We begin our research endeavors with a solid foundation for study design and methodology. We have conducted systematic reviews of the current state of computerized assessments, led focus groups with primary care physicians to learn about their confidence and methods for diagnosing brain disorders, and reviewed qualitative results from feasibility studies in primary care settings.
We believe all novel assessments should be backed with evidence-based support before being used in clinical care. We have performed several types of validation with our tasks with sensitivity and specificity analyses, concurrent validity analyses, neuroanatomical validity analyses, and validation in several language adaptations across the globe.
Studies aimed at discovering links between TabCAT and biomarkers play a crucial role in early detection and diagnosis, treatment monitoring over time, and predicting change over time. We have seen significant associations between our tests and Aβ-PET and tau-PET status, and continue to perform research in this exciting field.
We believe in health equity for all, and the need for accessible tools is growing. We continue to validate our tools in multiple language adaptations, examine social determinants of health, and explore neurocognitive disorders in underserved populations such as those experiencing homelessness.
The TabCAT-BHA tests are associated with gold standard imaging biomarkers of Alzheimer’s disease and may useful for identifying patients with suspected Alzheimer’s disease pathology.
The TabCAT-BHA is accurate for detecting mild cognitive impairment and dementia in Spanish-speaking older adults in Cuba.
This paper discusses benefits and limitations of digital assessment tools in clinical practice and provides an overview of advances in tablet- and smartphone-based technologies for cognitive testing.
The TabCAT-BHA Cognitive Score, a summary metric of memory, executive, and language tests, is accurate for detecting cognitive impairment in English- and Spanish-speaking older adults and is sensitive to earliest cognitive changes related to Alzheimer’s disease.